RxDoctor Payments Data

Michael Hopkins, MD

Hematology & Oncology · Edenton, NCNPI 1063474526

Payments from drug & device makers

$10,616in general payments, 2019–2025

Across 458 payments — averaging $23.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Scientific Affairs, LLC$2K
  • Novartis$933
  • Merck$846
  • Johnson & Johnson$840
  • AstraZeneca$794
  • Sanofi$468
  • plus $5K from 45 others

What the payments were for

  • Consulting fees$1,51514%
  • Food & beverage$9,07986%
  • Education$230%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,616 in reported general payments places this provider in the 50th percentile of 358 hematology & oncology providers in North Carolina.

See all hematology & oncology providers in North Carolina

Medicare billing

Part B allowed, 2024
$79,504
Medicare patients
225
Services billed
893

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PomalystPomalidomide17$387,334
ImbruvicaIbrutinib11$180,451
KisqaliRibociclib Succinate12$170,637
Abiraterone Acetate12$95,582
XareltoRivaroxaban18$14,594
Cyclosporine12$5,031
Anastrozole94$1,316
Morphine Sulfate ErMorphine Sulfate24$812
Hydroxyurea44$748
Dexamethasone27$471
Acyclovir38$444
Letrozole13$412
Tamoxifen Citrate12$304
Levothyroxine Sodium31$285
Prochlorperazine Maleate22$254

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$319$387,33417 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$106$180,45111 claims
NovartisKisqali$933$170,63712 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$1,801$95,58212 claims
Johnson & JohnsonXarelto$840$14,59418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 358 hematology & oncology providers in North Carolina.

Other hematology & oncology in Edenton

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →